Jonathan S Cebon

11PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 24, 2026
Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial.

|Sep 11, 2025
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal

|Jul 02, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

Georgina V Long, Caroline Robert, Marcus O Butler

|Sep 17, 2020
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.

Pouya Faridi, Katherine Woods, Simone Ostrouska

|Jul 02, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.

Matteo S Carlino, Alexander M Menzies, Victoria Atkinson

|Jun 26, 2020
Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma.

Jennifer Eom, Saem Mul Park, Vaughan Feisst

Pageof 2

Frequent Collaborators

5 joint publications

Andreas Behren

3 joint publications

Jodie Palmer

2 joint publications

Ashray Gunjur

2 joint publications

Simone Ostrouska